Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Onlymyhealth on MSN1d
WHO Warns Of HIV Drug Shortages In Nigeria, Kenya And Other NationsThe World Health Organization (WHO) has issued a grave warning about an imminent HIV drug shortage in several countries ...
Researchers have discovered that Daphne pseudomezereum (commonly known as Onishibari) contains a substance inhibiting ...
The CDC's $1.3 billion Division of HIV Prevention is tasked with tracking infections across the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback